Equity Overview
Price & Market Data
Price: $1.16
Daily Change: +$0.004 / 0.34%
Range: $1.10 - $1.17
Market Cap: $13,614,261
Volume: 3,420
Performance Metrics
1 Week: 9.81%
1 Month: -10.46%
3 Months: -18.60%
6 Months: -18.60%
1 Year: -39.06%
YTD: -16.86%
Company Details
Employees: 1
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts.